Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Lintuzumab-Ac225

Radiopharmaceutical · Kills target cells, directed at CD33 · developed by Actinium Pharmaceuticals

Phase 1/2 Most advanced trial (none active)

ATNM Developer

1 Registered trials

What is Lintuzumab-Ac225?

Lintuzumab-Ac225 (Actimab) is a radiolabeled antibody that carries the alpha-emitting radionuclide actinium-225. It is studied in relapsed acute myeloid leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Actimab
Drug type: Radiopharmaceutical
Targets: CD33
Mechanism: Kills target cells, directed at CD33
Therapy area: Oncology
Developer: Actinium Pharmaceuticals (ATNM)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03867682	Phase 1/2	Acute Myeloid Leukemia	Unknown	ATNM

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myeloid LeukemiaRelapsed Adult AML

Other drugs acting on CD33

Actinium Ac 225 Lintuzumab Phase 1 BI 836858 Phase 2/3 Lintuzumab Phase 1

More from Actinium Pharmaceuticals

131I-apamistamab Phase 2/3 Iodine I 131 Apamistamab Phase 3 Lintuzumab Phase 1

Sources

ClinicalTrials.gov NCT03867682

Updated Oct 11, 2026. Something wrong or missing? Report it on the ATNM page.

Follow ATNM, the company behind Lintuzumab-Ac225

See ATNM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ATNM catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z